Aesthetics & Skincare
Glutathione
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Aesthetics Detox
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous, Intramuscular
Typical vial sizes: 1000, 1500 mg
Dosing window: Anytime
Receptor / target: Antioxidant
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 100mg 1x daily | Standard / Gradual Approach (2 mL = 300 mg/mL). Six days per week. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mg | Initiation. |
| Weeks 3-4 | 150 mg | Escalation. |
| Weeks 5-8 | 200 mg | Peak dose phase. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Cosmetic protocols are usually built around local tissue signaling and slow visible change. The logic is conservative exposure, site rotation where relevant, and stopping escalation when irritation, pigment changes, or metal-related issues appear. Entry context: target (Antioxidant); route Subcutaneous/Intramuscular; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Asthma (inhaled form only): the contraindication is route-specific; nebulized/inhaled glutathione has been associated with bronchospasm in asthmatic subjects; the subcutaneous and intramuscular injectable routes used in this database do not carry this bronchospasm risk. Limited / unverified
- Concurrent chemotherapy agents that rely on oxidative mechanism for cancer cell killing (alkylating agents, platinum compounds: cisplatin, carboplatin, oxaliplatin): glutathione is a primary detoxification mechanism for these drugs; elevated intracellular GSH in cancer cells is a known mechanism of chemotherapy resistance; exogenous glutathione during platinum-based or alkylating chemotherapy could reduce chemotherapy efficacy through enhanced cancer cell GSH-mediated drug detoxification. Limited / unverified
- Concurrent nitroglycerin therapy: glutathione is required for the bioactivation of organic nitrates; paradoxically, GSH depletion is the mechanism of nitrate tolerance, and high-dose exogenous glutathione could restore nitrate sensitivity abruptly in subjects who have developed tolerance. Limited / unverified
- Known hypersensitivity to glutathione, its tripeptide components (γ-glutamic acid, cysteine, glycine), or formulation excipients. Limited / unverified
- Severe renal impairment: the kidneys play a role in glutathione metabolism and cysteine recycling; in severe renal failure the pharmacokinetics of exogenous GSH are altered. Limited / unverified
- Wilson's disease (copper overload disorder): glutathione participates in copper metabolism through its cysteine thiol group; in Wilson's disease where copper accumulation is the pathological problem, alterations in glutathione-mediated copper handling require medical supervision. Limited / unverified
Side effects (limited evidence)
- Injection site pain: the most consistently reported adverse effect; glutathione at concentrations of 200-300mg/mL is slightly acidic and can produce notable injection site burning and soreness compared to standard peptide injections; most pronounced with IM administration; managed by slower injection rate and warming the solution to body temperature. Limited / unverified
- Skin lightening and loss of melanin: the intended cosmetic effect becomes an adverse effect in subjects who did not desire pigmentation reduction or who experience uneven lightening; the effect is dose-dependent, progressive over weeks, and reversible upon discontinuation but gradual in reversal. Limited / unverified
- Uneven skin lightening: hypopigmentation may be patchy rather than uniform, particularly at injection sites (local concentration effect) versus systemic distribution; typically equilibrates with continued use as systemic distribution homogenizes. Limited / unverified
- Zinc depletion: sustained high-dose glutathione supplementation has been associated with reduced serum zinc; zinc supplementation concurrent with long-term glutathione cycles is advisable. Limited / unverified
- Mild gastrointestinal discomfort (uncommon at injectable doses): not a primary concern with subcutaneous/IM routes versus oral. Limited / unverified
- Temporary worsening of melanoma surveillance: glutathione's tyrosinase inhibition and melanin reduction effects could theoretically alter the appearance of melanocytic lesions in a manner that affects dermatological surveillance; all existing moles should be documented before initiating glutathione cycles. Limited / unverified
- Paradoxical pro-oxidant effect at very high doses: at supraphysiological concentrations, the GSH/GSSG redox couple can shift in a pro-oxidant direction; this is a theoretical concern at doses far exceeding the standard protocol and not clinically observed at the 100-200mg doses used in these protocols. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.